Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

Pharmaceutical Manufacturing

Houston, Texas 2,828 followers

Groundbreaking Cancer Therapies

About us

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of soft tissue sarcoma (STS) lung metastases and relapsed or refractory acute myeloid leukemia (AML). Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.

Industry
Pharmaceutical Manufacturing
Company size
2-10 employees
Headquarters
Houston, Texas
Type
Public Company
Founded
2006

Locations

Employees at Moleculin Biotech, Inc.

Updates

Similar pages

Browse jobs

Funding

Moleculin Biotech, Inc. 8 total rounds

Last Round

Post IPO equity

US$ 5.5M

See more info on crunchbase